Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Reumatología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 2
ClinicalTrials.gov
Randomized, Double-blind, Placebo Controlled, Proof of Concept Study Assessing the Efficacy and Safety of the RIPK1-inhibitor SAR443122 in Patients With Moderate to Severe Subacute or Discoid/Chronic Cutaneous Lupus Erythematosus
INTERVENTIONAL
Inicio: 1 de abr de 2021
ID: NCT04781816
Terminado
Fase 2
ClinicalTrials.gov
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus
INTERVENTIONAL
Inicio: 23 de sept de 2015
ID: NCT02665364
Completado
ClinicalTrials.gov
Analysis of Brain Responses and Habituation to Multimodal Sensory Stimuli in Patients With Fibromyalgia
OBSERVATIONAL
Inicio: 14 de mar de 2025
ID: NCT06905171
Completado
Fase 2
ClinicalTrials.gov
A Phase 2, Long-Term Extension (LTE) Study With Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599) in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus Who Have Completed the M19-130 Phase 2 Randomized Controlled Trial (RCT)
INTERVENTIONAL
Inicio: 27 de jul de 2020
ID: NCT04451772
Completado
Fase 3
ClinicalTrials.gov
A Double-Blind, Randomized, Parallel-Arm, Multicenter Study to Determine the Dose Response of Methotrexate (MTX) in Combination Therapy With Adalimumab in Subjects With Early Rheumatoid Arthritis (CONCERTO)
INTERVENTIONAL
Inicio: 1 de oct de 2010
ID: NCT01185301
Completado
Fase 2
ClinicalTrials.gov
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus
INTERVENTIONAL
Inicio: 19 de ago de 2020
ID: NCT04433585
Por invitación
Fase 2
ClinicalTrials.gov
An Open-Label Extension Study to Assess Long-term Safety and Tolerability of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
INTERVENTIONAL
Inicio: 28 de ago de 2025
ID: NCT07188844
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE 2)
INTERVENTIONAL
Inicio: 7 de mar de 2019
ID: NCT03671148
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
INTERVENTIONAL
Inicio: 8 de mar de 2012
ID: NCT01550003
Reclutando
Fase 3
ClinicalTrials.gov
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002)
INTERVENTIONAL
Inicio: 10 de mar de 2025
ID: NCT06671496
Completado
Fase 3
ClinicalTrials.gov
Multicenter Non-Comparative Expanded Access Program of to Assess Safety of Rituximab (Mab Anti Cd-20) in Patients With Rheumatoid Arthritis (Ser)
INTERVENTIONAL
Inicio: 1 de feb de 2006
ID: NCT00502996
Completado
Fase 3
ClinicalTrials.gov
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
INTERVENTIONAL
Inicio: 1 de ene de 2008
ID: NCT00624338
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Multicentre Randomized Double-Blind Placebo Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
INTERVENTIONAL
Inicio: 15 de feb de 2022
ID: NCT05138133
Completado
Fase 3
ClinicalTrials.gov
(OSKIRA-3): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients With Inadequate Response to a TNF-alpha Antagonist
INTERVENTIONAL
Inicio: 1 de sept de 2010
ID: NCT01197755
Activo, no recluta
Fase 2
ClinicalTrials.gov
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Deucravacitinib (BMS-986165) in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
INTERVENTIONAL
Inicio: 12 de jul de 2021
ID: NCT04857034
Reclutando
Fase 3
ClinicalTrials.gov
A Multicenter, Randomized Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Upadacitinib With a Tocilizumab Reference Arm in Subjects From 1 Year to Less Than 18 Years Old With Active Systemic Juvenile Idiopathic Arthritis
INTERVENTIONAL
Inicio: 2 de oct de 2023
ID: NCT05609630
Completado
Fase 2
ClinicalTrials.gov
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
INTERVENTIONAL
Inicio: 1 de jun de 2012
ID: NCT02015520
Terminado
Fase 2
ClinicalTrials.gov
A Multicenter, Randomized, Double-Blind Comparison of 4 Dose Regimens of Pla-695, Naproxen, and Placebo Administered Daily for 6 Weeks in Subjects With Active Osteoarthritis of the Knee
INTERVENTIONAL
Inicio: 1 de nov de 2006
ID: NCT00396955
Terminado
Fase 2
ClinicalTrials.gov
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Two-Arm, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LY3361237 as a Treatment for Adults With At Least Moderately Active Systemic Lupus Erythematosus
INTERVENTIONAL
Inicio: 7 de mar de 2022
ID: NCT05123586
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Placebo-controlled Study to Evaluate the Effect of Tocilizumab on Disease Response in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA), With an Open-label Extension to Examine the Long Term Use of Tocilizumab
INTERVENTIONAL
Inicio: 1 de may de 2008
ID: NCT00642460
Anterior
1
...
8
9
10
...
434
Siguiente
Filtros